Antibody-drug conjugates, most, if not all, are immunotoxins but use whole antibodies and non-protein drugs
The research groups of Professor Hendrik Fuchs (Charité University, Berlin, Germany) and Dr David Flavell (Southampton General Hospital, United Kingdom) are working together toward the development of Gypsophila saponins for use in combination with immunotoxins or other targeted toxins for patients with leukaemia, lymphoma and other cancers.